Context Therapeutics Inc (CNTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.20+4.90%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CNTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
CNTX — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-07-31
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 29, 2026, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum…
Why it matters: Starting the next trial stage would show progress in the main program for ovarian cancer resistant to platinum.
Supportive ifThe company reports that CTIM-76 Phase 1b has started by the end of Q1 2027.
Worry ifThe company reports that the Phase 1b start slipped past Q1 2027 or was paused.
Why it matters: The first data can test whether the drug acts in tumors while limiting activity elsewhere. That is central to its design.
Watch forInitial Phase 1a data in 2H 2027 show tumor responses. No severe safety issues occur.
Also watch forThe data show no tumor responses, severe safety issues, or a delay past 2H 2027.
Why it matters: Starting the trial would turn CT-202's full economic rights into a clinical test. The company gave a Q3 2026 start target.
Supportive ifA company filing or trial record confirms the first patient was treated by September 30, 2026.
Worry ifNo first patient is reported by September 30, 2026, or the trial start is delayed or paused.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$350 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $926 loss on $10,000 · 9.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,437 loss on $10,000 · 94.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.